BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
2000
BCL-2 Protein and Ovarian Cancer Drug Resistance
Sample size: 12
publication
Evidence: moderate
Author Information
Author(s): Beale P J, Rogers P, Boxall F, Sharp S Y, Kelland L R
Primary Institution: CRC Centre for Cancer Therapeutics, Institute of Cancer Research
Hypothesis
Does the expression of BCL-2 family proteins correlate with platinum drug resistance in ovarian carcinoma?
Conclusion
High levels of BCL-2 in ovarian carcinoma cells may actually make them more sensitive to platinum drugs rather than resistant.
Supporting Evidence
- There was a significant inverse correlation between growth inhibition by cisplatin and BCL-2 levels.
- Overexpression of BCL-2 in sensitive ovarian cancer cells led to resistance to cisplatin at 48 hours but increased sensitivity at 96 hours.
- No consistent pattern of BCL-2 expression was found in resistant ovarian cancer cell lines.
Takeaway
This study found that having more BCL-2 protein in ovarian cancer cells might help them respond better to certain cancer drugs.
Methodology
The study measured BCL-2 family protein levels in 12 ovarian carcinoma cell lines and assessed their sensitivity to cisplatin.
Statistical Information
P-Value
0.002
Statistical Significance
p=0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website